Scarica l'app Stockscreener
15.69
1.62%
0.25
Dopo l'orario di chiusura:
15.73
0.04
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ADPT Giù?
Forum
Previsione
Precedente Chiudi:
$15.44
Aprire:
$16.03
Volume 24 ore:
3.00M
Relative Volume:
1.34
Capitalizzazione di mercato:
$2.40B
Reddito:
$205.22M
Utile/perdita netta:
$-121.24M
Rapporto P/E:
-19.27
EPS:
-0.8141
Flusso di cassa netto:
$-82.81M
1 W Prestazione:
+4.95%
1M Prestazione:
+11.28%
6M Prestazione:
+52.03%
1 anno Prestazione:
+149.05%
Intervallo 1D:
$15.35
$16.08
Intervallo di 1 settimana:
$14.69
$16.26
Portata 52W:
$5.805
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Nome
Adaptive Biotechnologies Corp
Settore
Industria
Telefono
206-659-0067
Indirizzo
1165 EASTLAKE AVE E, SEATTLE, WA
Confronta ADPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
15.69 | 2.36B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-02 | Ripresa | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Iniziato | Guggenheim | Buy |
| 2025-06-18 | Iniziato | Craig Hallum | Buy |
| 2025-03-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-12-21 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Underperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Reiterato | BTIG Research | Buy |
| 2022-02-16 | Reiterato | BofA Securities | Buy |
| 2022-02-16 | Reiterato | Goldman | Neutral |
| 2022-02-16 | Reiterato | JP Morgan | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-03-03 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Iniziato | Goldman | Buy |
| 2019-07-23 | Iniziato | BTIG Research | Buy |
| 2019-07-22 | Iniziato | BofA/Merrill | Buy |
| 2019-07-22 | Iniziato | Cowen | Outperform |
| 2019-07-22 | Iniziato | Goldman | Neutral |
| 2019-07-22 | Iniziato | Guggenheim | Buy |
| 2019-07-22 | Iniziato | William Blair | Outperform |
Mostra tutto
Adaptive Biotechnologies Corp Borsa (ADPT) Ultime notizie
Pfizer Faces Another Quiet Year As Patent Losses Cloud 2026 Outlook: Analyst - Benzinga
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M - Investing.com
Adaptive Biotechnologies inks two agreements with Pfizer in immunology - Investing.com India
Adaptive signs deal with Pfizer worth up to $890 million for rheumatoid arthritis research - Reuters
Adaptive Biotechnologies stock rises after Pfizer deals worth up to $890M By Investing.com - Investing.com South Africa
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million - Yahoo Finance
Adaptive (NASDAQ: ADPT) signs RA TCR, data licensing pacts with Pfizer (NYSE: PFE) - Stock Titan
Insider Sell: Robert Hershberg Sells 22,968 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Take off with Adaptive Biotechnologies Corp (ADPT): Get ready for trading - setenews.com
Adaptive Biotechnologies to Discuss clonoSEQ Technology and Minimal Residual Disease at Jefferies Fireside Chat - Quiver Quantitative
Adaptive Biotechnologies to Participate in Jefferies Fireside Chat Series on Minimal Residual Disease - Yahoo Finance
Adaptive Biotechnologies chief commercial officer sells $212k in stock - Investing.com
Adaptive Biotechnologies (ADPT) Falls 24.5% as Execs Dispose Millions of Stake - Insider Monkey
Adaptive Biotechnologies CEO Chad M Robins Sells $3M in Company Shares - StocksToTrade
Adaptive Biotechnologies (ADPT) Showcases clonoSEQ Test Advances at ASH Meeting - GuruFocus
Adaptive Biotechnologies Stock Declines After Insider Sale - timothysykes.com
December Disappointments: 10 Big Names Troubled Early - Insider Monkey
Seattle InnoLayoffs at Adaptive I Rover's marketing efforts - The Business Journals
Adaptive Biotechnologies’ Stock Faces Turmoil Amid Insider Selling - StocksToTrade
Adaptive Biotechnologies Corporation Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ Data Driving Treatment Interventions at 2025 ASH Annual Meeting - marketscreener.com
Adaptive Biotechnologies Highlights Expanded Clinical Use of clonoSEQ® Test at 67th ASH Annual Meeting - Quiver Quantitative
Adaptive Biotechnologies (Nasdaq: ADPT) shows clonoSEQ MRD guiding blood cancer care at ASH 2025 - Stock Titan
Insider Sell: Harlan Robins Sells 37,212 Shares of Adaptive Biot - GuruFocus
Adaptive Biotechnologies CSO Robins sells $672,515 in ADPT stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CSO Robins sells $672,515 in ADPT stock - Investing.com
Adaptive Biotechnologies Exec Sells Over $670K in Company Stock - TradingView
Officer Robins Sells 37,212 ($672.5K) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Why Is Adaptive Biotechnologies Stock Trading Lower After Natera's Over $400 Million Deal? - Benzinga
Adaptive Biotechnologies (ADPT) Is Down 11.2% After Earnings Beat And CFO Share SaleHas The Bull Case Changed? - simplywall.st
Will Adaptive Biotechnologies Corporation stock beat EPS estimatesDollar Strength & AI Enhanced Trading Alerts - Newser
Officer Robins Files To Sell 10,000 Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Will Adaptive Biotechnologies Corporation (1HM) stock draw ESG focused funds2025 Earnings Surprises & Stock Portfolio Risk Control - Newser
Will Adaptive Biotechnologies Corporation (1HM) stock sustain uptrend momentum2025 Dividend Review & Real-Time Volume Analysis Alerts - Newser
Assessing Adaptive Biotechnologies (ADPT) Valuation After a 179% One-Year Rebound and Recent Pullback - Yahoo Finance
Ready to Jump After Recent Trade: Adaptive Biotechnologies Corp (ADPT) - setenews.com
Adaptive biotechnologies CFO Piskel sells $3.17 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $2,367,462.12 in Stock - MarketBeat
ADPT FinancialsIncome Statement - Quiver Quantitative
Adaptive biotechnologies CFO Piskel sells $3.17 million in stock - Investing.com
Adaptive Biotechnologies CFO Kyle Piskel Sells Over 162K Shares - TradingView
CFO Piskel Sells 162,820 ($3.2M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Adaptive Biotechnologies (ADPT) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ameritas Investment Partners Inc. Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - Defense World
Chad Robins Sells 160,734 Shares of Adaptive Biotechnologies Cor - GuruFocus
Adaptive Biotechnologies CEO Robins sells $3.07 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CEO Robins sells $3.07 million in stock - Investing.com
Adaptive Biotechnologies CEO Sells Shares Worth Over $3 Million - TradingView
Chmn Robins Sells 160,734 ($3.1M) Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Chmn Robins Files To Sell 124,998 Of Adaptive Biotechnologies Corp [ADPT] - TradingView
CFO Piskel Files To Sell 162,820 Of Adaptive Biotechnologies Corp [ADPT] - TradingView
Adaptive Biotechnologies Corp Azioni (ADPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):